5 March 2021 - Late treatment study
The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients
et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107531 (Peer Reviewed)
Retrospective 311 severe condition hospitalized patients in China, 123 treated with probiotics, showing slower viral clearance and recovery with treatment. Authors note that probiotics were able to moderate immunity and decrease the incidence of secondary infections.
|
risk of no hospital discharge, 11.8% higher, RR 1.12, p = 0.68, treatment 30 of 123 (24.4%), control 41 of 188 (21.8%).
|
|
time to discharge, 60.0% higher, relative time 1.60, p < 0.001, treatment 123, control 188.
|
|
time to viral-, 35.3% higher, relative time 1.35, p < 0.001, treatment 123, control 188.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Li et al., 3/5/2021, retrospective, China, Asia, peer-reviewed, 7 authors, average treatment delay 13.0 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.